Paliperidone, Serum or Plasma
Ordering Recommendation

Optimize drug therapy and monitor patient adherence. This test detects paliperidone (9-hydroxyrisperidone) only. For risperidone (parent) AND paliperidone (9-hydroxyrisperidone, metabolite), order Risperidone and Metabolite, Serum or Plasma (2007951).

Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Sun, Wed
1-5 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Pre-dose (trough) draw - At steady state concentration. 
Lavender (EDTA), pink (K2EDTA) or plain red. 
Specimen Preparation
Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.5 mL) 
Storage/Transport Temperature
Unacceptable Conditions
Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution). 
Submit With Order
Please indicate in the supplied fields:
1.  Dose - List drug amount and include the units of measure
2.  Route - List the route of administration (IV, oral, etc.)
3.  Dose Frequency - Indicate how often the dose is administered (per day, per week, as needed, etc.)
4.  Type of Draw - Indicate the type of blood draw (Peak, Trough, Random, etc.) 
Ambient: 2 weeks; Refrigerated: 2 weeks; Frozen: 2 months 
Reference Interval
Therapeutic range:Not well established
Proposed Dose-Related Range:Paliperidone (9-hydroxyrisperidone): 20 - 60 ng/mL
Toxic range:Not well established

Interpretive Data
The therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration. Adverse effects to paliperidone therapy may include headache, nausea, dizziness, tachycardia, orthostatic hypotension and dyskinesia.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Hotline History
CPT Code(s)
Component Test Code*Component Chart NameLOINC
2007950Paliperidone, Serum/Plasma9383-1
2011545Paliperidone Dose
2011546Paliperidone Dose Frequency82777-4
2011547Paliperidone Route45373-8
2011548Paliperidone Type of Draw
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • 9-hydroxyrisperidone
  • Invega
  • invega blood level